GemPharmatech（688046）株式概要株式会社ジェムファーマテック（GemPharmatech Co, Ltd.）は、受託研究機関として、世界中の科学コミュニティに遺伝子改変マウスモデルと前臨床研究サービスを提供しています。 詳細688046 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長1/6過去の実績4/6財務の健全性5/6配当金3/6報酬当社が推定した公正価値より3.7%で取引されている 収益は年間18.59%増加すると予測されています 過去1年間で収益は44.8%増加しました リスク分析リスクチェックの結果、688046 、リスクは検出されなかった。すべてのリスクチェックを見る688046 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueCN¥Current PriceCN¥20.9044.5% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture02b2016201920222025202620282031Revenue CN¥1.7bEarnings CN¥332.5mAdvancedSet Fair ValueView all narrativesGemPharmatech Co., Ltd. 競合他社Suzhou Sepax TechnologiesSymbol: SHSE:688758Market cap: CN¥8.3bBeijing Sun-Novo Pharmaceutical ResearchSymbol: SHSE:688621Market cap: CN¥6.1bHitGenSymbol: SHSE:688222Market cap: CN¥12.6bPharmaResources (Shanghai)Symbol: SZSE:301230Market cap: CN¥5.3b価格と性能株価の高値、安値、推移の概要GemPharmatech過去の株価現在の株価CN¥20.9052週高値CN¥21.9952週安値CN¥11.50ベータ1.01ヶ月の変化6.96%3ヶ月変化22.80%1年変化80.17%3年間の変化-1.04%5年間の変化n/aIPOからの変化2.25%最新ニュースBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Bo Yu was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 23GemPharmatech Co., Ltd., Annual General Meeting, May 14, 2026GemPharmatech Co., Ltd., Annual General Meeting, May 14, 2026, at 10:00 China Standard Time. Location: No. 12, Xuefu Road, Jiangbei New District, Nanjing, Jiangsu Chinaお知らせ • Mar 30GemPharmatech Co., Ltd. to Report Q1, 2026 Results on Apr 23, 2026GemPharmatech Co., Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026お知らせ • Dec 26GemPharmatech Co., Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026GemPharmatech Co., Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026お知らせ • Sep 30GemPharmatech Co., Ltd. to Report Q3, 2025 Results on Oct 23, 2025GemPharmatech Co., Ltd. announced that they will report Q3, 2025 results on Oct 23, 2025お知らせ • Jun 30GemPharmatech Co., Ltd. to Report First Half, 2025 Results on Aug 23, 2025GemPharmatech Co., Ltd. announced that they will report first half, 2025 results on Aug 23, 2025最新情報をもっと見るRecent updatesBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Bo Yu was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 23GemPharmatech Co., Ltd., Annual General Meeting, May 14, 2026GemPharmatech Co., Ltd., Annual General Meeting, May 14, 2026, at 10:00 China Standard Time. Location: No. 12, Xuefu Road, Jiangbei New District, Nanjing, Jiangsu Chinaお知らせ • Mar 30GemPharmatech Co., Ltd. to Report Q1, 2026 Results on Apr 23, 2026GemPharmatech Co., Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026お知らせ • Dec 26GemPharmatech Co., Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026GemPharmatech Co., Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026お知らせ • Sep 30GemPharmatech Co., Ltd. to Report Q3, 2025 Results on Oct 23, 2025GemPharmatech Co., Ltd. announced that they will report Q3, 2025 results on Oct 23, 2025お知らせ • Jun 30GemPharmatech Co., Ltd. to Report First Half, 2025 Results on Aug 23, 2025GemPharmatech Co., Ltd. announced that they will report first half, 2025 results on Aug 23, 2025お知らせ • Apr 26GemPharmatech Co., Ltd., Annual General Meeting, May 28, 2025GemPharmatech Co., Ltd., Annual General Meeting, May 28, 2025, at 10:00 China Standard Time. Location: No. 12, Xuefu Road, Jiangbei New District, Nanjing, Jiangsu Chinaお知らせ • Mar 28GemPharmatech Co., Ltd. to Report Q1, 2025 Results on Apr 26, 2025GemPharmatech Co., Ltd. announced that they will report Q1, 2025 results on Apr 26, 2025お知らせ • Dec 27GemPharmatech Co., Ltd. to Report Fiscal Year 2024 Results on Apr 26, 2025GemPharmatech Co., Ltd. announced that they will report fiscal year 2024 results on Apr 26, 2025お知らせ • Nov 08GemPharmatech Co., Ltd. (SHSE:688046) announces an Equity Buyback for CNY 40 million worth of its shares.GemPharmatech Co., Ltd. (SHSE:688046) announces a share repurchase program. Under the program, the company will repurchase up to CNY 40 million worth of its shares. The shares will be purchased at a price not exceeding CNY 18 per share. The purpose of the program is to improve the company's long-term incentive mechanism, fully mobilize the enthusiasm of the employees, and jointly promote the company's long-term development. The repurchased shares will be used for employee stock ownership plans or equity incentive plans, otherwise will be cancelled if the company fails to transfer them within the time limit stipulated by relevant laws and regulations. The program will be funded from company's own funds and the special loan funds. The program will be valid for 12 months. The company had 410,000,000 shares outstanding.Reported Earnings • Nov 02Third quarter 2024 earnings released: EPS: CN¥0.052 (vs CN¥0.10 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.052 (down from CN¥0.10 in 3Q 2023). Revenue: CN¥169.3m (up 6.7% from 3Q 2023). Net income: CN¥21.9m (down 46% from 3Q 2023). Profit margin: 13% (down from 25% in 3Q 2023). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Life Sciences industry in China.お知らせ • Oct 25NeoMab Biotechnology (Suzhou) Co., Ltd. Launches the Innovative NeoMab-IgG Ease ModelNeoMab Biotechnology (Suzhou) Co., Ltd., a wholly-owned subsidiary of GemPharmatech launched the innovative NeoMab-IgG Ease model, based on its next-generation fully human antibody transgenic mouse model—NeoMab. This advancement marks another significant breakthrough for NeoMab in the field of antibody drug development. The NeoMab-IgG Ease model simplifies the antibody drug development process significantly with its unique "milestone-free, live mouse provision" approach, making commercial collaboration more efficient and convenient. NeoMab mice utilize human V(D)J gene-encoded antibodies, exhibiting gene usage frequency and sequence diversity similar to humans, making them suitable for fully human antibody development. Their competent immune system is capable of efficiently performing antigen presentation, antibody production, and affinity maturation. The unique BALB/c genetic background and antigen presentation system enhance the ability to present antigens, with serum titers reaching 10^5 to 10^6 after 3-4 rounds of immunizations, promoting the generation of high-affinity antibodies. SPR testing shows that the antibody affinities of NeoMab mice range from 10^-8 to 10^-10, meeting various needs for fully humanized antibody development. NeoMab is committed to providing convenient one-stop services for its clients. The NeoMab-IgG Ease model employs a "milestone-free, live mouse provision" business model, eliminating lengthy negotiations and milestone payment processes. Clients can directly obtain live mice for immunization, allowing for the rapid development of fully human therapeutic antibodies. This streamlined collaboration enhances flexibility and optimizes the complex payment and agreement processes typical of traditional business models. Through the NeoMab platform, clients can access the NeoMab models and have the opportunity to obtain a variety of fully human building blocks such as IgG, ScFv, and Fab, catering to the development of various drug types and cell therapies, including ADCs, AOCs, and mono/bi/multispecific antibodies and nanobodies. NeoMab provides a comprehensive range of services from target validation to IND filing, ensuring a seamless experimental process. By integrating antibody screening with in vivo experimental animal models, NeoMab significantly accelerates the in vivo animal study process and eliminates the costs associated with humanization, helping clients shorten drug development timelines by up to 1.5 years. Partners have expressed their recognition and affirmation of NeoMab's services in accelerating the research and development process.Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to CN¥12.95, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 22x in the Life Sciences industry in China. Total loss to shareholders of 22% over the past year.お知らせ • Sep 30GemPharmatech Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024GemPharmatech Co., Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥12.71, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 22x in the Life Sciences industry in China. Total loss to shareholders of 25% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥25.20 per share.お知らせ • Jun 28GemPharmatech Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024GemPharmatech Co., Ltd. announced that they will report first half, 2024 results on Aug 29, 2024お知らせ • Apr 29GemPharmatech Co., Ltd., Annual General Meeting, Jun 13, 2024GemPharmatech Co., Ltd., Annual General Meeting, Jun 13, 2024, at 10:00 China Standard Time. Location: No. 12, Xuefu Road, Jiangbei New District, Nanjing, Jiangsu Chinaお知らせ • Mar 30GemPharmatech Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024GemPharmatech Co., Ltd. announced that they will report Q1, 2024 results on Apr 27, 2024Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥15.53, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 23x in the Life Sciences industry in China.Reported Earnings • Feb 24Full year 2023 earnings released: EPS: CN¥0.39 (vs CN¥0.42 in FY 2022)Full year 2023 results: EPS: CN¥0.39 (down from CN¥0.42 in FY 2022). Revenue: CN¥622.2m (up 21% from FY 2022). Net income: CN¥159.0m (down 3.5% from FY 2022). Profit margin: 26% (down from 32% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 27% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Life Sciences industry in China.Valuation Update With 7 Day Price Move • Feb 12Investor sentiment improves as stock rises 17%After last week's 17% share price gain to CN¥12.78, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 20x in the Life Sciences industry in China.Valuation Update With 7 Day Price Move • Jan 26Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to CN¥13.98, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 23x in the Life Sciences industry in China.お知らせ • Dec 30GemPharmatech Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024GemPharmatech Co., Ltd. announced that they will report fiscal year 2023 results on Apr 27, 2024お知らせ • Dec 27GemPharmatech Co., Ltd. (SHSE:688046) announces an Equity Buyback for CNY 40 million worth of its shares.GemPharmatech Co., Ltd. (SHSE:688046) announces a share repurchase program. Under the program, the company will repurchase up to CNY 40 million worth of class A shares. The shares will be repurchased at a price of not more than CNY 29 per share. The shares purchased will be used for the company's equity incentive plan or ESOP. The program will be valid till 12 months.Reported Earnings • Nov 02Third quarter 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.11 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.10 (down from CN¥0.11 in 3Q 2022). Revenue: CN¥158.7m (up 17% from 3Q 2022). Net income: CN¥40.1m (down 14% from 3Q 2022). Profit margin: 25% (down from 34% in 3Q 2022). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in China.Reported Earnings • Sep 01Second quarter 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.14 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.11 (down from CN¥0.14 in 2Q 2022). Revenue: CN¥155.6m (up 16% from 2Q 2022). Net income: CN¥46.5m (down 9.3% from 2Q 2022). Profit margin: 30% (down from 38% in 2Q 2022). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in China.お知らせ • Aug 22GemPharmatech Co., Ltd. Introduced NeoMabGemPharmatech announced the launch of NeoMab™, independently developed fully antibody gene humanized mouse model, after four years of rigorous research and validation. NeoMab™ is specifically designed to meet the burgeoning therapeutic antibody development demands of biotechnology companies and pharmaceutical enterprises. NeoMab™ is developed on the widely recognized BALB/c genetic background, rendering it highly suitable for antibody discovery. This model retains the native mouse constant region encoding genes while incorporating human variable gene repertoires into endogenous loci. This strategy gives rise to a formidable model that synergizes the strengths of the mouse immune system with human-specific variable regions, making it an ideal candidate for propelling antibody discovery and innovative research. Through extensive in vitro and in vivo experimentation, the NeoMab™ mouse model has exhibited the following exceptional attributes: Human-Like Variable Gene Usage Frequency: NeoMab™ mice employ human V(D)J genes to encode antibodies, mirroring gene usage frequency and sequence diversity remarkably similar to those observed in humans. Competent Immune System: NeoMab™ mice maintain an intact immune system, with proportions of diverse immune cell subsets akin to those found in BALB/c mice. Uninterrupted B-Cell Development: NeoMab™ mice demonstrate unimpeded antibody class switching, somatic hypermutation, and B-cell development. These mice showcase immunoglobulin levels in their serum comparable to those in BALB/c background mice. Robust Immune Response: After immunization with antigens, NeoMab™ mice exhibit antigen-specific serum titers similar to BALB/c mice. The antibodies derived from the NeoMab™ mouse model offer the following advantages: High Affinity: Antibodies obtained from NeoMab™ mice exhibit an affinity range of approximately 10-10 to 10-8 (as assessed by SPR detection), comparable to or even surpassing that of FDA-approved therapeutic antibody drugs. Effective In Vitro and In Vivo Functionality: The in vitro functional activity and in vivo efficacy of NeoMab™-derived antibodies closely mirror those observed in FDA-approved therapeutic antibody drugs. Reduced Risk of Immunogenicity: These antibodies are less likely to trigger immune responses, due to their higher success rate attributed to the human antibody gene background. NeoMab™, a fully antibody gene humanized model from GemPharmatech, synergizes seamlessly with advanced technical platform. It not only streamlines preclinical discovery and validation processes for forward-thinking pharmaceutical enterprises but also leverages licensing agreements and high-throughput screening platforms to expedite objectives efficiently and cost-effectively. This approach optimizes capital investment and galvanizes innovative drug development, ultimately paving the way for advancements in the field. GemPharmatech's commitment to advancing disease mechanism research, pharmaceutical development, and translational studies is exemplified through array of model resources and support services. Repository encompasses KOAP mice and tool mice tailored for drug screening, providing invaluable resources for target validation and pharmacological efficacy investigations. Additionally, meticulously developed research service platforms span prominent domains such as oncology, metabolism, cardiovascular sciences, immunology, and neuroscience. By harnessing the synergy between these platforms and model resources, the company deliver comprehensive non-clinical research services across diverse fields. NeoMab™, fully antibody gene humanized model, stands as a pivotal addition within the GemPharmatech portfolio. This innovative platform seamlessly integrates with expansive model resources and professional technical service platforms, elevating antibody research and discovery endeavors. Through this harmonious fusion, the company empower drug development enterprises with comprehensive support, expediting the journey of uncovering and advancing new therapeutic agents.New Risk • Jun 12New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 38% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. High level of non-cash earnings (38% accrual ratio).Board Change • May 19Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Bo Yu was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.株主還元688046CN Life SciencesCN 市場7D-2.8%-0.2%-0.04%1Y80.2%39.5%34.9%株主還元を見る業界別リターン: 688046過去 1 年間で39.5 % の収益を上げたCN Life Sciences業界を上回りました。リターン対市場: 688046過去 1 年間で34.9 % の収益を上げたCN市場を上回りました。価格変動Is 688046's price volatile compared to industry and market?688046 volatility688046 Average Weekly Movement8.0%Life Sciences Industry Average Movement6.5%Market Average Movement6.4%10% most volatile stocks in CN Market10.1%10% least volatile stocks in CN Market4.2%安定した株価: 688046 、 CN市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 688046の 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト20171,590Jing Zhaowww.gempharmatech.comジェムファーマテック株式会社（GemPharmatech Co., Ltd.）は、受託研究機関であり、世界中の科学コミュニティに遺伝子操作マウスモデルと前臨床研究サービスを提供している。同社は、ノックアウトマウス、コンディショナルノックアウトマウス、疾患マウス、免疫不全マウス、無菌マウス、ツールマウスモデルなどのマウスモデルを提供し、野生マウスプロジェクトも運営している。また、カスタムモデル作製、前臨床試験、無菌およびマイクロバイオーム、細胞株およびカスタマイズ、カスタム繁殖、動物品質試験、その他のサービスも提供している。同社は2017年に設立され、中国の南京に本社を置いている。もっと見るGemPharmatech Co., Ltd. 基礎のまとめGemPharmatech の収益と売上を時価総額と比較するとどうか。688046 基礎統計学時価総額CN¥8.55b収益（TTM）CN¥159.76m売上高(TTM)CN¥830.61m53.5xPER（株価収益率10.3xP/Sレシオ688046 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計688046 損益計算書（TTM）収益CN¥830.61m売上原価CN¥300.58m売上総利益CN¥530.03mその他の費用CN¥370.27m収益CN¥159.76m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）0.39グロス・マージン63.81%純利益率19.23%有利子負債／自己資本比率6.9%688046 の長期的なパフォーマンスは？過去の実績と比較を見る配当金1.1%現在の配当利回り55%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 10:42終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋GemPharmatech Co., Ltd. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Kai WangCitic Securities Co., Ltd.Yiling ChenGuosen Securities Co., Ltd.Qianli MaGuosen Securities Co., Ltd.3 その他のアナリストを表示
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Bo Yu was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 23GemPharmatech Co., Ltd., Annual General Meeting, May 14, 2026GemPharmatech Co., Ltd., Annual General Meeting, May 14, 2026, at 10:00 China Standard Time. Location: No. 12, Xuefu Road, Jiangbei New District, Nanjing, Jiangsu China
お知らせ • Mar 30GemPharmatech Co., Ltd. to Report Q1, 2026 Results on Apr 23, 2026GemPharmatech Co., Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026
お知らせ • Dec 26GemPharmatech Co., Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026GemPharmatech Co., Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026
お知らせ • Sep 30GemPharmatech Co., Ltd. to Report Q3, 2025 Results on Oct 23, 2025GemPharmatech Co., Ltd. announced that they will report Q3, 2025 results on Oct 23, 2025
お知らせ • Jun 30GemPharmatech Co., Ltd. to Report First Half, 2025 Results on Aug 23, 2025GemPharmatech Co., Ltd. announced that they will report first half, 2025 results on Aug 23, 2025
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Bo Yu was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 23GemPharmatech Co., Ltd., Annual General Meeting, May 14, 2026GemPharmatech Co., Ltd., Annual General Meeting, May 14, 2026, at 10:00 China Standard Time. Location: No. 12, Xuefu Road, Jiangbei New District, Nanjing, Jiangsu China
お知らせ • Mar 30GemPharmatech Co., Ltd. to Report Q1, 2026 Results on Apr 23, 2026GemPharmatech Co., Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026
お知らせ • Dec 26GemPharmatech Co., Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026GemPharmatech Co., Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026
お知らせ • Sep 30GemPharmatech Co., Ltd. to Report Q3, 2025 Results on Oct 23, 2025GemPharmatech Co., Ltd. announced that they will report Q3, 2025 results on Oct 23, 2025
お知らせ • Jun 30GemPharmatech Co., Ltd. to Report First Half, 2025 Results on Aug 23, 2025GemPharmatech Co., Ltd. announced that they will report first half, 2025 results on Aug 23, 2025
お知らせ • Apr 26GemPharmatech Co., Ltd., Annual General Meeting, May 28, 2025GemPharmatech Co., Ltd., Annual General Meeting, May 28, 2025, at 10:00 China Standard Time. Location: No. 12, Xuefu Road, Jiangbei New District, Nanjing, Jiangsu China
お知らせ • Mar 28GemPharmatech Co., Ltd. to Report Q1, 2025 Results on Apr 26, 2025GemPharmatech Co., Ltd. announced that they will report Q1, 2025 results on Apr 26, 2025
お知らせ • Dec 27GemPharmatech Co., Ltd. to Report Fiscal Year 2024 Results on Apr 26, 2025GemPharmatech Co., Ltd. announced that they will report fiscal year 2024 results on Apr 26, 2025
お知らせ • Nov 08GemPharmatech Co., Ltd. (SHSE:688046) announces an Equity Buyback for CNY 40 million worth of its shares.GemPharmatech Co., Ltd. (SHSE:688046) announces a share repurchase program. Under the program, the company will repurchase up to CNY 40 million worth of its shares. The shares will be purchased at a price not exceeding CNY 18 per share. The purpose of the program is to improve the company's long-term incentive mechanism, fully mobilize the enthusiasm of the employees, and jointly promote the company's long-term development. The repurchased shares will be used for employee stock ownership plans or equity incentive plans, otherwise will be cancelled if the company fails to transfer them within the time limit stipulated by relevant laws and regulations. The program will be funded from company's own funds and the special loan funds. The program will be valid for 12 months. The company had 410,000,000 shares outstanding.
Reported Earnings • Nov 02Third quarter 2024 earnings released: EPS: CN¥0.052 (vs CN¥0.10 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.052 (down from CN¥0.10 in 3Q 2023). Revenue: CN¥169.3m (up 6.7% from 3Q 2023). Net income: CN¥21.9m (down 46% from 3Q 2023). Profit margin: 13% (down from 25% in 3Q 2023). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Life Sciences industry in China.
お知らせ • Oct 25NeoMab Biotechnology (Suzhou) Co., Ltd. Launches the Innovative NeoMab-IgG Ease ModelNeoMab Biotechnology (Suzhou) Co., Ltd., a wholly-owned subsidiary of GemPharmatech launched the innovative NeoMab-IgG Ease model, based on its next-generation fully human antibody transgenic mouse model—NeoMab. This advancement marks another significant breakthrough for NeoMab in the field of antibody drug development. The NeoMab-IgG Ease model simplifies the antibody drug development process significantly with its unique "milestone-free, live mouse provision" approach, making commercial collaboration more efficient and convenient. NeoMab mice utilize human V(D)J gene-encoded antibodies, exhibiting gene usage frequency and sequence diversity similar to humans, making them suitable for fully human antibody development. Their competent immune system is capable of efficiently performing antigen presentation, antibody production, and affinity maturation. The unique BALB/c genetic background and antigen presentation system enhance the ability to present antigens, with serum titers reaching 10^5 to 10^6 after 3-4 rounds of immunizations, promoting the generation of high-affinity antibodies. SPR testing shows that the antibody affinities of NeoMab mice range from 10^-8 to 10^-10, meeting various needs for fully humanized antibody development. NeoMab is committed to providing convenient one-stop services for its clients. The NeoMab-IgG Ease model employs a "milestone-free, live mouse provision" business model, eliminating lengthy negotiations and milestone payment processes. Clients can directly obtain live mice for immunization, allowing for the rapid development of fully human therapeutic antibodies. This streamlined collaboration enhances flexibility and optimizes the complex payment and agreement processes typical of traditional business models. Through the NeoMab platform, clients can access the NeoMab models and have the opportunity to obtain a variety of fully human building blocks such as IgG, ScFv, and Fab, catering to the development of various drug types and cell therapies, including ADCs, AOCs, and mono/bi/multispecific antibodies and nanobodies. NeoMab provides a comprehensive range of services from target validation to IND filing, ensuring a seamless experimental process. By integrating antibody screening with in vivo experimental animal models, NeoMab significantly accelerates the in vivo animal study process and eliminates the costs associated with humanization, helping clients shorten drug development timelines by up to 1.5 years. Partners have expressed their recognition and affirmation of NeoMab's services in accelerating the research and development process.
Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to CN¥12.95, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 22x in the Life Sciences industry in China. Total loss to shareholders of 22% over the past year.
お知らせ • Sep 30GemPharmatech Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024GemPharmatech Co., Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥12.71, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 22x in the Life Sciences industry in China. Total loss to shareholders of 25% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥25.20 per share.
お知らせ • Jun 28GemPharmatech Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024GemPharmatech Co., Ltd. announced that they will report first half, 2024 results on Aug 29, 2024
お知らせ • Apr 29GemPharmatech Co., Ltd., Annual General Meeting, Jun 13, 2024GemPharmatech Co., Ltd., Annual General Meeting, Jun 13, 2024, at 10:00 China Standard Time. Location: No. 12, Xuefu Road, Jiangbei New District, Nanjing, Jiangsu China
お知らせ • Mar 30GemPharmatech Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024GemPharmatech Co., Ltd. announced that they will report Q1, 2024 results on Apr 27, 2024
Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥15.53, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 23x in the Life Sciences industry in China.
Reported Earnings • Feb 24Full year 2023 earnings released: EPS: CN¥0.39 (vs CN¥0.42 in FY 2022)Full year 2023 results: EPS: CN¥0.39 (down from CN¥0.42 in FY 2022). Revenue: CN¥622.2m (up 21% from FY 2022). Net income: CN¥159.0m (down 3.5% from FY 2022). Profit margin: 26% (down from 32% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 27% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Life Sciences industry in China.
Valuation Update With 7 Day Price Move • Feb 12Investor sentiment improves as stock rises 17%After last week's 17% share price gain to CN¥12.78, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 20x in the Life Sciences industry in China.
Valuation Update With 7 Day Price Move • Jan 26Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to CN¥13.98, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 23x in the Life Sciences industry in China.
お知らせ • Dec 30GemPharmatech Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024GemPharmatech Co., Ltd. announced that they will report fiscal year 2023 results on Apr 27, 2024
お知らせ • Dec 27GemPharmatech Co., Ltd. (SHSE:688046) announces an Equity Buyback for CNY 40 million worth of its shares.GemPharmatech Co., Ltd. (SHSE:688046) announces a share repurchase program. Under the program, the company will repurchase up to CNY 40 million worth of class A shares. The shares will be repurchased at a price of not more than CNY 29 per share. The shares purchased will be used for the company's equity incentive plan or ESOP. The program will be valid till 12 months.
Reported Earnings • Nov 02Third quarter 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.11 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.10 (down from CN¥0.11 in 3Q 2022). Revenue: CN¥158.7m (up 17% from 3Q 2022). Net income: CN¥40.1m (down 14% from 3Q 2022). Profit margin: 25% (down from 34% in 3Q 2022). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in China.
Reported Earnings • Sep 01Second quarter 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.14 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.11 (down from CN¥0.14 in 2Q 2022). Revenue: CN¥155.6m (up 16% from 2Q 2022). Net income: CN¥46.5m (down 9.3% from 2Q 2022). Profit margin: 30% (down from 38% in 2Q 2022). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in China.
お知らせ • Aug 22GemPharmatech Co., Ltd. Introduced NeoMabGemPharmatech announced the launch of NeoMab™, independently developed fully antibody gene humanized mouse model, after four years of rigorous research and validation. NeoMab™ is specifically designed to meet the burgeoning therapeutic antibody development demands of biotechnology companies and pharmaceutical enterprises. NeoMab™ is developed on the widely recognized BALB/c genetic background, rendering it highly suitable for antibody discovery. This model retains the native mouse constant region encoding genes while incorporating human variable gene repertoires into endogenous loci. This strategy gives rise to a formidable model that synergizes the strengths of the mouse immune system with human-specific variable regions, making it an ideal candidate for propelling antibody discovery and innovative research. Through extensive in vitro and in vivo experimentation, the NeoMab™ mouse model has exhibited the following exceptional attributes: Human-Like Variable Gene Usage Frequency: NeoMab™ mice employ human V(D)J genes to encode antibodies, mirroring gene usage frequency and sequence diversity remarkably similar to those observed in humans. Competent Immune System: NeoMab™ mice maintain an intact immune system, with proportions of diverse immune cell subsets akin to those found in BALB/c mice. Uninterrupted B-Cell Development: NeoMab™ mice demonstrate unimpeded antibody class switching, somatic hypermutation, and B-cell development. These mice showcase immunoglobulin levels in their serum comparable to those in BALB/c background mice. Robust Immune Response: After immunization with antigens, NeoMab™ mice exhibit antigen-specific serum titers similar to BALB/c mice. The antibodies derived from the NeoMab™ mouse model offer the following advantages: High Affinity: Antibodies obtained from NeoMab™ mice exhibit an affinity range of approximately 10-10 to 10-8 (as assessed by SPR detection), comparable to or even surpassing that of FDA-approved therapeutic antibody drugs. Effective In Vitro and In Vivo Functionality: The in vitro functional activity and in vivo efficacy of NeoMab™-derived antibodies closely mirror those observed in FDA-approved therapeutic antibody drugs. Reduced Risk of Immunogenicity: These antibodies are less likely to trigger immune responses, due to their higher success rate attributed to the human antibody gene background. NeoMab™, a fully antibody gene humanized model from GemPharmatech, synergizes seamlessly with advanced technical platform. It not only streamlines preclinical discovery and validation processes for forward-thinking pharmaceutical enterprises but also leverages licensing agreements and high-throughput screening platforms to expedite objectives efficiently and cost-effectively. This approach optimizes capital investment and galvanizes innovative drug development, ultimately paving the way for advancements in the field. GemPharmatech's commitment to advancing disease mechanism research, pharmaceutical development, and translational studies is exemplified through array of model resources and support services. Repository encompasses KOAP mice and tool mice tailored for drug screening, providing invaluable resources for target validation and pharmacological efficacy investigations. Additionally, meticulously developed research service platforms span prominent domains such as oncology, metabolism, cardiovascular sciences, immunology, and neuroscience. By harnessing the synergy between these platforms and model resources, the company deliver comprehensive non-clinical research services across diverse fields. NeoMab™, fully antibody gene humanized model, stands as a pivotal addition within the GemPharmatech portfolio. This innovative platform seamlessly integrates with expansive model resources and professional technical service platforms, elevating antibody research and discovery endeavors. Through this harmonious fusion, the company empower drug development enterprises with comprehensive support, expediting the journey of uncovering and advancing new therapeutic agents.
New Risk • Jun 12New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 38% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. High level of non-cash earnings (38% accrual ratio).
Board Change • May 19Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Bo Yu was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
